Correction to: Prostate Cancer and Prostatic Diseases 10.1038/s41391-023-00711-0, published online 07 September 2023
The following paragraph
Radiotracers that are approved by the Food and Drug Administration (FDA) for use in patients with PCa include carbon 11 (11C)-choline, fluorine 18 (18F)-sodium fluoride, 18F-fluciclovine (Axumin®, Blue Earth Diagnostics, Inc., Oxford, UK), gallium 68 (68Ga)-PSMA-11 (institutional use only in US), and 2-(3-{1-carboxy-5-[(6-18F-fluoropyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (18F-DCFPyL; PYLARIFY®, Progenics Pharmaceuticals, Inc. North Billerica, MA; US only).
should read:
Radiotracers that are approved by the Food and Drug Administration (FDA) for use in patients with PCa include carbon 11 (11C)-choline, fluorine 18 (18F)-sodium fluoride, 18F-fluciclovine (Axumin®, Blue Earth Diagnostics, Inc., Oxford, UK), gallium 68 (68Ga)-PSMA-11, and 2-(3-{1-carboxy-5-[(6-18F-fluoropyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (18F-DCFPyL; PYLARIFY®, Progenics Pharmaceuticals, Inc. North Billerica, MA). Access to radiotracers will continue to evolve, therefore, it is recommended to check regulatory authorities in specific countries for current approvals.